In California, Zymergen raised $500 million last week in its IPO and its stock has cruised up from the IPO price of $31 a share to close on Friday at $39.88, up 29 percent from its Wednesday trading debut. The company sold an unexpectedly robust $16.1 million shares at $31, the top end of its expected range.
In short, every sign from the market is bullish.
For many companies, the hard yards to be gained lie in developing and sustaining public confidence there are reliably profitable media companies selling at 3.5 times earnings, to quote an example. It’s clear that Zymergen has mastered the arts of communicating a story for, with $13 million in revenue and $260 million in losses last year, to go with $12 million in revenue and $240 million in losses in 2019, Zymergen is one of the definitive story stocks.
by Christopher J. Guske and Mark Warner (D2 Biotech Consulting/Warner Advisors/Biofuels Digest) … “Capital Light is great until you run out of someone else’s capital.” As multi-decade Industrial Biotech veterans, we are seeing more start-up companies “dressed up with nowhere to go.”
How dire it this situation? It is definitely getting worse at the wrong time. North America contract research and manufacturing organization (CRO/CMO) capacity is tightening. In 2020, one CRO/CMO completely shut down its facility to all fermentation work and laid off staff. A second quit conducting outside work as internal demand filled capacity. A third was rumored to be considering shutting down or selling.
The Coming Apocalypse: Will Industrial Biotech Flourish or Flounder? : Biofuels Digest biofuelsdigest.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biofuelsdigest.com Daily Mail and Mail on Sunday newspapers.